Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Deloitte
Medtronic
McKesson
Daiichi Sankyo
Queensland Health
Harvard Business School
QuintilesIMS
Chinese Patent Office
Fuji

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 091671

« Back to Dashboard

NDA 091671 describes HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX, which is a drug marketed by Neos Therap Inc and is included in one NDA. It is available from two suppliers. Additional details are available on the HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX profile page.

The generic ingredient in HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX is chlorpheniramine polistirex; hydrocodone polistirex. There are twenty-nine drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the chlorpheniramine polistirex; hydrocodone polistirex profile page.
Summary for 091671
Pharmacology for NDA: 091671
Suppliers and Packaging for NDA: 091671
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX chlorpheniramine polistirex; hydrocodone polistirex SUSPENSION, EXTENDED RELEASE;ORAL 091671 ANDA Atlantic Biologicals Corps 17856-0301 17856-0301-1 72 CUP in 1 CASE (17856-0301-1) > 5 mL in 1 CUP
HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX chlorpheniramine polistirex; hydrocodone polistirex SUSPENSION, EXTENDED RELEASE;ORAL 091671 ANDA Neos Therapeutics, LP 62542-301 62542-301-16 473 mL in 1 BOTTLE, GLASS (62542-301-16)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SUSPENSION, EXTENDED RELEASE;ORALStrengthEQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML
Approval Date:Jun 29, 2012TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Cipla
Johnson and Johnson
Harvard Business School
Covington
Chinese Patent Office
US Army
Novartis
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot